|Neil Clark, Chief Executive Officer
Mr Clark qualified as an accountant with PwC in Cambridge, UK and worked for over ten years on a variety of national and international assignments in audit, corporate finance and consultancy. In 1997, Mr Clark joined CeNeS Pharmaceuticals plc, a venture capital backed private UK biotech company. Following the successful flotation of CeNeS in 1999, he was appointed CFO. In 2005, he became CEO and led the company through to its sale in 2008. Mr Clark then joined Ergomed in January 2009 and was CFO during its IPO in July 2014 until his move to be full time CEO of PrimeVigilance (Ergomed’s successful drug safety business) in January 2016. Mr Clark is a Fellow of the Institute of Chartered Accountants in England and Wales and has a BSc in Bioscience from the University of Nottingham.
|Dr William Love, Founder and Chief Scientific Officer
Dr Love was a senior scientist at Ciba Geigy/Novartis focused on novel drug delivery technologies and involved in the development of the world’s leading eye-care pharmaceutical, Visudyne. In 1997, Dr Love founded Destiny Pharma and he is the co-inventor of the XF drug platform. Dr Love was a founding member of the BEAM Alliance, an EU SME group focused on promoting antimicrobial drug development. He is an expert advisory board member of Global AMR Innovation Fund, appointed by Professor Dame Sally Davies in October 2016. Dr Love is the named inventor in more than 70 patents. He has experience in drug R&D from discovery and lead identification, through pre-clinical development and into Phase 1/2 clinical development in the UK, EU and US.
|Shaun Claydon, Chief Financial Officer and Company Secretary
Mr Claydon is an accomplished corporate financier and qualified Chartered Accountant with over 16 years’ board level experience, including within the biotechnology sector. He has extensive experience of delivering financial and operating results and from 2015 served as CFO of Creabilis, a venture backed clinical stage specialty pharmaceutical company focused on dermatology treatments, during which he led the $150 million sale of the business to Sienna Biopharmaceuticals. From 2009 to 2014 Mr Claydon was CFO and chief operating officer of Orteq Sports Medicine, a medical device company and world leader in the field of biodegradable polymer technologies. Prior to these positions Mr Claydon held a number of senior financial consultancy and corporate finance roles including at PwC, Evolution Beeson Gregory (now Investec) and HSBC Investment Banking.
|Dr Jesus Gonzalez Moreno, Chief Medical Officer
Dr González is an infectious disease expert with more than 11 years’ experience of working within global pharmaceutical and biotechnology companies in drug development, medical affairs and marketing authorisation submissions.
He most recently served as Global Clinical Development Director at TiGenix SAU where he was responsible for the overall development strategy for a stem cell treatment for sepsis secondary to community-acquired pneumonia. Prior to that Dr González worked at Basilea Pharmaceutica as Medical Science Liaison team leader, responsible for the global medical plan for anti-infectives and he has also held medical director roles at AstraZeneca and MSD within their anti-infectives divisions.
Dr González is a licensed physician with a medical doctor degree from the Universidad Autónoma de Madrid, Spain. He also received a master’s degree in Statistics and Study Design for Research in the Health Sciences from the Universidad Autónoma de Barcelona and completed a postdoctoral fellowship in emerging and re-emerging infectious diseases at the Uniformed Services University of the Health Sciences, Department of Defence, Maryland, US.
|Dr Stephanie Bewick, Chief Business Officer
Dr Bewick has 20 years’ experience in Business Development within public and private biotech companies as well as mid-sized pharma, both in-house and as a consultant. Most recently, she was Vice President, Business Development at Summit Therapeutics, a NASDAQ-listed infectious disease company, leading the out-licensing and in-licensing activities, pipeline positioning and technology valuation, and was also involved in pre-launch activities to support commercialisation of an asset in the US. Throughout her career she has negotiated and closed a range of transactions from early research phase to late clinical stage of development. She holds a BSc (Hons) Neuroscience from the University of Edinburgh and a PhD from the University of Bristol.